DERM
Journey Medical Corporation
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$7.86
−0.51%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 68.2M | 61.9M | 56.1M | 79.2M | 73.7M |
| Cost of Revenue | 25.7M | 25.2M | 20.9M | 26.7M | 30.8M |
| Gross Profit | 42.4M | 36.7M | 35.3M | 52.5M | 42.9M |
| Operating Expenses | |||||
| R&D Expense | 495.0K | 480.0K | 9.9M | 7.5M | 10.9M |
| SG&A Expense | 30.9M | 44.4M | 40.2M | 43.9M | 59.5M |
| General & Admin Expense | 10.9M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 14.1M | — | (1.1M) | 3.1M | — |
| Total Operating Expenses | 45.4M | 44.8M | 48.9M | 54.6M | 70.4M |
| Cost and Expenses | 71.2M | 70.0M | 69.8M | 81.3M | 101.2M |
| Operating Income (EBIT) | (3.0M) | (8.2M) | (13.7M) | (2.1M) | (27.5M) |
| Non-Operating | |||||
| Interest Income | 613.0K | 589.0K | 757.0K | 322.0K | 60.0K |
| Interest Expense | 3.7M | 3.7M | 2.7M | 1.7M | 2.0M |
| Net Interest Income | (3.1M) | (3.1M) | (1.9M) | (1.4M) | (2.0M) |
| Other Non-Op Income/Expense | (3.1M) | (3.2M) | (934.0K) | (1.6M) | (2.0M) |
| Non-Operating Income (excl Interest) | (587.0K) | (499.0K) | (1.8M) | (139.0K) | 29.0K |
| EBT (Pre-Tax Income) | (6.1M) | (11.4M) | (14.6M) | (3.6M) | (29.6M) |
| Income Tax Expense | 15.0K | 60.0K | 61.0K | 221.0K | 63.0K |
| Bottom Line | |||||
| Net Income | (6.1M) | (11.4M) | (14.7M) | (3.9M) | (29.6M) |
| Earnings from Cont. Ops | (6.1M) | (11.4M) | (14.7M) | (3.9M) | (29.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (6.1M) | (11.4M) | (14.7M) | (3.9M) | (29.6M) |
| Per Share | |||||
| Basic EPS | ($0.23) | ($0.47) | ($0.72) | ($0.21) | ($1.69) |
| Diluted EPS | ($0.23) | ($0.47) | ($0.72) | ($0.21) | ($1.69) |
| Revenue Per Share | $2.48 | $2.53 | $2.75 | $4.34 | $4.20 |
| Shares | |||||
| Basic Shares Outstanding | 27.5M | 24.5M | 20.4M | 18.2M | 17.5M |
| Diluted Shares Outstanding | 27.5M | 24.5M | 20.4M | 18.2M | 17.5M |
| Profitability Metrics | |||||
| EBITDA | 1.8M | (3.3M) | (8.4M) | 1.9M | (23.2M) |
| D&A | 4.3M | 4.3M | 3.5M | 3.9M | 4.4M |
| EBIT | (2.4M) | (7.7M) | (11.9M) | (1.9M) | (27.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026